Alembic Pharmaceuticals Limited has informed the stock exchanges that the company has obtained tentative approval from the US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) concerning Ivosidenib Tablets, 250 mg. This approved ANDA is deemed therapeutically equivalent to Tibsovo Tablets, 250 mg, the reference listed drug product (RLD) marketed …